EUCTR2020-001709-21-FRActive, not recruitingPhase 1
Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolism in coronavirus disease 2019 (COVID-19) hospitalized patients : The randomized multicentric controlled open-label trial COVI-DOSE
CHRU de Nancy0 sites550 target enrollmentStarted: April 16, 2020Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 550
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Having been given an informed consent to participate or consent from relatives in case of vital emergency (patients not able to give a consent)
- •-Hospitalization for a acute respiratory COVID-19 infection probable or confirmed
- •-SARS-Cov-2 infection diagnosed by biology (positive PCR for COVID-19 on a nasophayngeal swab or any other saple and/or serological method) or by a composite criterium associating lung injury on imaging and clinical / biological symptoms suggestive of COVID-19 (eg : dyspnea, cough, fever, biological inflammatory syndrome, lymphopenia, elevated liver enzymes).
- •- Health Insurance Coverage
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 230
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 320
Exclusion Criteria
- •-End-stage kidney disease (glomerular filtration rate < 15 mL/min/1.73m²)
- •-Acute kidney failure KDIGO 3
- •-Having received at least 3 doses prophylaxis of low molecular weight heparin before the inclusion
- •-Therapeutic-dose of anticoagulant treatment for more than 24 hours, whatever the route or the drug prescribed for an other indication such as atrial fibrillation, thomboembolic venous disease needing an prolonged treatment, prosthetic heart valves, ...
- •-Iterative catheter-related thrombosis or thrombosis of an extracorporeal membrane oxygenation
- •- ECMO to be implemented within 24 hours.
- •-All contraindication to treatment with low molecular weight heparin
- •-High hemorrhagic risk: resistant systolic (> 180 mmHg) or diastolic (> 110 mmHg) hypertension during more than 12 hours or needing an intravenous treatment, recent (< 7j) major bleeding or non-resolved bleeding, coagulopathy (INR>2N ou ACT>2N), thrombocytopenia < 75 G/L, heparin-induced thrombocytopenia, contraindication to blood-derived products
- •-Lower limb Venous Doppler ultrasound not feasible (bilateral transfemoral amputation, or severe burns)
- •- Death expected within 48 hours
- •- Persons referred in articles L.1121-5 to L.1121-8 and L.1122-2 of the Public Health Code:
- •oPregnant, parturient or breastfeeding woman;
- •oPerson deprived of liberty for judicial or administrative decision;
- •oPerson under psychiatric care;
- •oMinor person (non-emancipated);
- •oAdult person under legal protection (any form of public guardianship).
Investigators
Similar Trials
Not yet recruiting
Phase 4
A study to determine effectiveness of Low Molecular Weight Heparin in reduction ofseverity of Acute PancreatitisCTRI/2022/12/048036Jawaharlal Institute of Postgraduate Medical Education and Research
Completed
Not Applicable
Effectiveness of low-molecular-weight heparin for prevention of deep venous thrombosis after surgery for colorectal cancer in Japanese patients: a randomized controlled phase III trialcolorectal cancerJPRN-UMIN000030582Tokyo Metropolitan Hiroo Hospital160
Completed
Phase 4
Highlow study: Low-molecular-weight heparin to prevent recurrent VTE in pregnancy: a randomized controlled trial of two dosespulmonary embolismNL-OMON55412Academisch Medisch Centrum200
Active, not recruiting
Phase 1
Highlow study:Prevention of recurrent deep vein thrombosis and lung embolism in pregnant womeEUCTR2012-001505-24-IEThe Rotunda Maternity Hospital850
Active, not recruiting
Phase 1
Highlow study:Prevention of recurrent deep vein thrombosis and lung embolism in pregnant womedeep vein thrombosispulmonary embolismMedDRA version: 18.0Level: LLTClassification code 10066529Term: Deep vein thrombosis recurrentSystem Organ Class: 100000004866MedDRA version: 18.0Level: LLTClassification code 10066738Term: Recurrent pulmonary embolismSystem Organ Class: 100000004855EUCTR2012-001505-24-BEAcademic Medical Center850